<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 19, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01169415</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00024406</org_study_id>
    <nct_id>NCT01169415</nct_id>
  </id_info>
  <brief_title>Effects of Steroid Tapering on Functional Capacity and Neurocognition</brief_title>
  <official_title>Effects of Dexamethasone Tapering Schedules on Functional Capacity and Neurocognition in Patients With Newly Diagnosed Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose and Objective:

        1. To compare the effects of either an abbreviated or protracted taper of dexamethasone on
           functional capacity in newly diagnosed glioblastoma multiforme (GBM) patients.

        2. To compare neurocognitive function in newly diagnosed GBM patients receiving either an
           abbreviated or protracted taper of dexamethasone.

        3. To compare skeletal muscle strength in newly diagnosed GBM patients receiving either an
           abbreviated or protracted taper of dexamethasone.

        4. To examine the association between functional capacity and neurocognitive function and
           patient-reported measures (i.e. quality of life, fatigue, etc.) in newly diagnosed GBM
           patient on either an abbreviated or protracted taper of dexamethasone.

        5. To examine the association between functional capacity and neurocognitive function and
           body composition measures (body-mass index, etc.) in newly diagnosed GBM patient on
           either an abbreviated or protracted taper of dexamethasone.

        6. To examine the association between functional capacity and neurocognitive function and
           biochemical metabolic measurements in newly diagnosed GBM patient on either an
           abbreviated or protracted taper of dexamethasone.

      All study endpoints will be assessed at three timepoints as follows: (1) initial assessment
      after surgery in the hospital, (2) second assessment at initial clinical visit at the
      Preston Robert Tisch Brain Tumor Center (PRT-BTC) at Duke, approximately 1 week
      post-operatively, and (3) third assessment at second clinical visit in the PRT-BTC at Duke,
      approximately 10 weeks post-operatively and after completion of radiotherapy.  An additional
      fourth assessment will be obtained at 4 weeks post-operatively if the subject is undergoing
      radiotherapy here at Duke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study is a randomized controlled trial.   After obtaining written informed
      consent, all participants will be randomized to either an abbreviated (14 days) or
      protracted (30 days) course of dexamethasone post-operatively.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Funding not obtained
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Functional Capacity (6-minute walk test)</measure>
    <time_frame>10 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The exercise test is designed to determine how far you can walk in six minutes.  This test will take place at the PRT-BTC at Duke University Medical Center and/or Duke University Medical Center inpatient unit on 4100 or 4300 with appropriate medical supervision.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Function</measure>
    <time_frame>10 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>A computerized neurocognitive test battery called CNS Vital SignsÂ® including verbal memory test, visual memory test, finger tapping test, symbol digit coding, Stroop test, shifting attention test, continuous performance test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal Muscle Strength</measure>
    <time_frame>10 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Isokinetic muscle strength for bilateral grip and bilateral quadriceps.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-Reported Outcomes (PROs)</measure>
    <time_frame>10 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed by standardized and validated questionnaires including: Depression (Beck Depression Inventory); Quality of Life (Functional Assessment of Cancer Therapy-Brain); Fatigue (Functional Assessment of Cancer Therapy-Fatigue); Cognition (Functional Assessment of Cancer Therapy-Cognition), Symptomalogy Index (Phone Questionnarie/Survery), Computerized Battery from CNS Vital Signs (Medical Outcomes Survey, Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Zung Self-Rating Depression Scale).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>10 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Body-mass index, weight, height, and circumference of the abdomen, hips, and quadriceps.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical metabolic measurements</measure>
    <time_frame>10 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hematocrit (%), albumin (g/mL), fasting blood glucose (mg/dL), fasting insulin (micro IU/mL), insulin like growth facto binding protein 1 (IGFBP-1) (ng/mL), cystatin C (mg/dL), and retinol binding protein 4 (RBP-4).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Protracted (30 days), Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a protracted course (30 days) of dexamethasone after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abbreviated (14 days), dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive an abbreviated (14 days) course of dexamethasone after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone acetate</intervention_name>
    <description>Participants will receive a protracted (30 days) course of dexamethasone after surgery.</description>
    <arm_group_label>Protracted (30 days), Dexamethasone</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Participants will receive a protracted (14 days) course of dexamethasone after surgery.</description>
    <arm_group_label>Abbreviated (14 days), dexamethasone</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. written informed consent prior to beginning specific protocol procedures,

          2. histologically proven GBM,

          3. status-post gross total resection or subtotal resection as indicated by &lt; 2 cm of
             residual enhancing disease (subjects with unresectable, multifocal, and /or bulky
             disease will be excluded),

          4. &gt;18 years and &lt;70 years of age,

          5. Karnofsky performance index &gt;70%,

          6. no documented cardiac, neurodegenerative, neuromuscular, or pulmonary disease,

          7. no contraindications to a 6-minute walk test,

          8. no contraindications to neurocognitive testing,

          9. primary treating physician approval, and

         10. no complications operatively or postoperatively that requires modification of
             dexamethasone dosing.

         11. receiving dexamethasone as standard of care.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine B Peters, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Health System</affiliation>
  </overall_official>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>June 25, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Randomized</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Abbreviated</keyword>
  <keyword>Protracted</keyword>
  <keyword>Post-operatively</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
